Non-Small Cell Lung Cancer
Conditions
Brief summary
This study was an open-label, multi-center, randomized phase III study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart versus Immunotherapy+ Platinum-based chemotherapy as First-Line treatment for patients with PD-L1-Positive locally advanced or metastatic NSCLC.
Detailed description
Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.
Interventions
SYS6010 is Lyophilized powder for injection as an EGFR-ADC. SYS6010 will be administered via intravenous infusion, Q3W, with 21 days as one treatment cycle, at a dose of 4.5 mg/kg.
Enlonstobart is arecombinant human anti-PD-1 monoclonal antibody injection，and will be administered by intravenous infusion, Q3W, with 21 days as one treatment cycle at a dosage of 360 mg.
Tislelizumab is a marketed recombinant human anti-PD-1 monoclonal antibody injection, and will be administered by intravenous infusion, Q3W, with 21 days as one treatment cycle at a dosage of 200 mg.
DRUGPaclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin
Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin are widely accepted and common chemotherapy medication. For squamous NSCLC, Paclitaxel+Carboplatin were recommended to be administrated on a 21-day cycle. For nonsquamous NSCLC, Pemetrexed + Cisplatin or Carboplatin were recommended to be administrated on a 21-day cycle.
Sponsors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Intervention model description
The patients will be randomized in a 1:1 ratio to SYS6010 combined with Enlonstobart or Tislelizumab+Platinum-based chemotherapy
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-75 (inclusive) years old, male or females; 2. Participants with pathologically confirmed locally advanced or metastatic NSCLC. Including participants with stage IIIB or IIIC according to the 9th edition of AJCC staging who are not suitable for surgical resection or radical chemoradiotherapy, or participants with stage IV NSCLC 3. Participants who have not previously received systemic anti-tumor treatment. Those who have previously received adjuvant/neoadjuvant therapy will be allowed for inclusion if disease progression occurs 12 months after the end of treatment. 4. EGFR mutation negative and ALK fusion negative 5. Participants with PD-L1 TPS≥1% according to centralized laboratory test 6. At least one measurable lesion confirmed by CT or MRI scan according to RECIST v1.1 criteria 7. ECOG performance status of 0-1; 8. Life expectancy ≥ 3 months; 9. Major organ function must meet the criteria within 7 days prior to the first dose of the study intervention 10. Women of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose. Participants must agree to use effective contraception from the time of signing the informed consent form until 7 months after the last dose; during this period, women should not be breastfeeding, and men should avoid donating sperm; 11. Voluntarily participate in this clinical study, understand the study procedures, and be able to sign a written informed consent form.
Exclusion criteria
1. Histology or cytology of the tumor confirms the presence of combined small cell lung cancer, neuroendocrine carcinoma, or sarcomatoid carcinoma; 2. Participants with ROS1/RET/NTRK fusions, MET exon 14 skipping mutation, or BRAF V600E mutation. 3. Participants with meningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or active CNS metastasis. Patients with supratentorial and/or cerebellar metastasis (i.e., without mesencephalon, pons, or medulla involvement) who have received local treatment, have achieved stability for at least 2 weeks prior to the first dose of the study intervention (imaging shows no new brain metastasis or enlargement of existing brain metastasis, and all neurologic symptoms have stabilized or returned to normal), and do not require corticosteroid therapy or are receiving prednisone at a daily dose of ≤10 mg or equivalent doses of other corticosteroids, can participate in the study; 4. Participants with a history of other malignant tumors within 3 years prior to the first dose of the study intervention, except for the following conditions: cured skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, and cervical carcinoma in situ, etc.; 5. Participants who are known to be allergic to any component of SYS6010, Enlonstobart, Tislelizumab or to humanized monoclonal antibody products or ; Paclitaxel/Carboplatin/ Pemetrexed/Cisplatin. 6. Previously treated with topoisomerase I inhibitor toxin ADC therapy 7. AEs caused by prior anti-tumor treatment have not recovered to ≤ Grade 1 (excluding Grade 2 alopecia and other toxicities judged by the investigator to have no safety risk) according to NCI-CTCAE v6.0; Participants who experienced ≥ grade 3 irAEs during previous treatment, or who permanently discontinued medication due to irAEs 8. Patients who have not met the corresponding washout period requirements for the medications or treatments should be excluded； 9. History of severe cardiovascular or cerebrovascular disease within 6 months prior to the first dose of the study intervention\\ 10. Patients who have a history of ILD/non-infectious pneumonitis treated with corticosteroids in the past, currently have ILD/non-infectious pneumonitis, for whom imaging examinations at screening cannot rule out ILD/non-infectious pneumonitis, or whose pulmonary function test indicates severe ventilatory dysfunction and/or decreased diffusion capacity; 11. Presence of severe infections within 4 weeks prior to the first dose of the study intervention, including but not limited to bacteraemia requiring hospitalisation, severe pneumonia, active pulmonary tuberculosis infection, etc.; presence of active infections requiring systemic antibiotics within 2 weeks prior to the first dose of the study intervention; 12. Participants with active autoimmune diseases or a history of autoimmune diseases (such as ulcerative colitis or Crohn's disease) are excluded, but participants with the following conditions are allowed to proceed to further enrollment screening: well-controlled type 1 diabetes and hypothyroidism that is well-controlled with only hormone replacement therapy. 13. Pleural effusion or pericardial effusion requiring clinical intervention within 2 weeks prior to the first dose; 14. Active HBV or HCV infection (hepatitis B surface antigen and/or hepatitis B core antibody positive and HBV DNA copies ≥ 1×10\^4 copies/mL or ≥ 2000 IU/mL, HCV antibody positive and HCV RNA above the lower limit of detection of the analytical procedure). Note: For HBsAg-positive patients, it is recommended to start antiviral therapy before the first dose of the study intervention, nucleoside analogues are recommended, such as entecavir, tenofovir disoproxil; 15. History of immunodeficiency (including positive HIV test, other acquired or congenital immunodeficiency diseases), history of allogeneic stem cell or organ transplant; 16. Other conditions that the investigator deem unsuitable for participation in this clinical study. Such as mental illness, uncontrolled or poorly controlled hypertension (defined as systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥95 mmHg after standardized antihypertensive treatment), and diabetes, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival (PFS) assessed by IRC | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | 2 years |
| ORR assessed by investigators and IRC | 1.5years |
| DoR assessed by investigators and IRC | 1.5years |
| The Proportion of ADAanti-drug antibody positive of SYS6010 and Enlonstobart | 1.5years |
| The severity and frequency of Adverse Event (AE)and Serious Adverse Event (SAE) assessed by CTCAE v6.0. | 2 years |
| Tmax of SYS6010 and Enlonstobart | 1.5 years |
| The Scale of Quality of Life assessed by participants | 2 years |
| Cmax of SYS6010 and Enlonstobart | 1.5 years |
| AUC0-504h of SYS6010 and Enlonstobart | 1.5 years |
| t1/2 of SYS6010 and Enlonstobart | 1.5 years |
| CL of SYS6010 and Enlonstobart | 1.5 years |
| Vz of SYS6010 and Enlonstobart | 1.5 years |
| DCR assessed by investigators and IRC | 1.5 years |
Contacts
CONTACTClinical Trials Information Group officer
Outcome results
None listed